Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Reinmuth

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
ESMO Open|March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANL Paz-Ares, Y Chen, N Reinmuth, et al.
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
Pneumologie (Stuttgart, Germany)|November 26, 2020
[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]M Lommatzsch, K F Rabe, C Taube, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
ESMO Open|March 13, 2022
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANL Paz-Ares, Y Chen, N Reinmuth, et al.
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
Pneumologie (Stuttgart, Germany)|November 26, 2020
[Risk Assessment for Patients with Chronic Respiratory and Pulmonary Conditions in the Context of the SARS-CoV-2 Pandemic - Statement of the German Respiratory Society (DGP) with the Support of the German Association of Respiratory Physicians (BdP)]M Lommatzsch, K F Rabe, C Taube, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)M Joerger, J von Pawel, S Kraff, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2026
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)N Frost, M Joosten, J Franzen, et al.
ESMO Open|July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in GermanyC Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
Pageof 5